Methylene blue and epinephrine: A synergetic association for anaphylactic shock treatment

Critical Care Medicine

Volumn 41, Issue 1, 2013, Pages 195-204

  Zheng, Feng ^a   Barthel, Grégoire ^a,b   Collange, Olivier ^c   Montémont, Chantal ^a   Thornton, Simon N ^a   Longrois, Dan ^d   Levy, Bruno ^a   Audibert, Gérard ^a,b   Malinovsky, Jean Marc ^a,e   Mertes, Paul Michel ^a,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d BICHAT HOSPITAL   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

anaphylaxis; cerebrovascular circulation; epinephrine; ischemia; methylene blue; microdialysis; nitric oxide; shock

Indexed keywords

ADRENALIN; CASPASE 3; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; METHYLENE BLUE; OVALBUMIN; PYRUVIC ACID;

ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD OXYGEN TENSION; BRAIN; BRAIN BLOOD FLOW; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EXCITOTOXICITY; HEART OUTPUT; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; WESTERN BLOTTING;

ANAPHYLAXIS; ANIMALS; BRAIN ISCHEMIA; CAPILLARY PERMEABILITY; CEREBROVASCULAR CIRCULATION; COMPARTMENT SYNDROMES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPINEPHRINE; MALE; METHYLENE BLUE; MUSCLE, SKELETAL; NITRIC OXIDE; PROSPECTIVE STUDIES; RATS; RATS, INBRED BN; VASOCONSTRICTOR AGENTS;

EID: 84872075477     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318267667b     Document Type: Article

References (49)

1. Mertes PM, Laxenaire MC, Lienhart A, et al; Working Group for the SFAR; ENDA; EAACI Interest Group on Drug Hypersensitivity: Reducing the risk of anaphylaxis during anaesthesia: Guidelines for clinical practice. J Investig Allergol Clin Immunol 2005; 15:91-101
2. Currie M, Webb RK, Williamson JA, et al: The Australian Incident Monitoring Study. Clinical anaphylaxis: An analysis of 2000 incident reports. Anaesth Intensive Care 1993, 21:621-625
3. Mitsuhata H, Matsumoto S, Hasegawa J: The epidemiology and clinical features of anaphylactic and anaphylactoid reactions in the perioperative period in Japan. Masui 1992; 41:1664-1669
4. Brown SG: Cardiovascular aspects of anaphylaxis: Implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5:359-364
5. Kemp SF, Lockey RF: Anaphylaxis: A review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341-348
6. Cui S, Shibamoto T, Zhang W, et al: Venous resistance increases during rat anaphylactic shock. Shock 2008; 29:733-739
7. Dewachter P, Jouan-Hureaux V, Franck P, et al: Anaphylactic shock: A form of distributive shock without inhibition of oxygen consumption. Anesthesiology 2005; 103:40-49
8. Karasawa N, Shibamoto T, Cui S, et al: Hepatic pre-sinusoidal vessels contract in anaphylactic hypotension in rabbits. Acta Physiol (Oxf) 2007; 189:15-22
9. Liu W, Takano H, Shibamoto T, et al: Involvement of splanchnic vascular bed in anaphylactic hypotension in anesthetized BALB/c mice. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1947-R1953
10. Miyahara T, Shibamoto T, Wang HG, et al: Role of circulating blood components and thromboxane in anaphylactic vasoconstriction in isolated canine lungs. J Appl Physiol 1997; 83:1508-1516
11. Czosnyka M, Brady K, Reinhard M, et al: Monitoring of cerebrovascular autoregulation: Facts, myths, and missing links. Neurocrit Care 2009; 10:373-386
12. Brown SG: Anaphylaxis: Clinical concepts and research priorities. Emerg Med Australas 2006; 18:155-169
13. Cauwels A, Janssen B, Buys E, et al: Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 2006; 116:2244-2251
14. Evora PR, Simon MR: Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. Ann Allergy Asthma Immunol 2007; 99:306-313
15. Joe EK, Schussheim AE, Longrois D, et al: Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase (iNOS): Mechanisms of contractile depression by nitric oxide. J Mol Cell Cardiol 1998; 30:303-315
16. Amir S, English AM: An inhibitor of nitric oxide production, NG-nitro-L-arginine-methyl ester, improves survival in anaphylactic shock. Eur J Pharmacol 1991; 203:125-127
17. Buzato MA, Viaro F, Piccinato CE, et al: The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: Experimental studies in rabbits. Shock 2005; 23:582-587
18. Takano H, Liu W, Zhao Z, et al: N(G)-nitro-L-arginine methyl ester, but not methylene blue, attenuates anaphylactic hypotension in anesthetized mice. J Pharmacol Sci 2007; 104:212-217
19. Andresen J, Shafi NI, Bryan RM Jr: Endothelial influences on cerebrovascular tone. J Appl Physiol 2006; 100:318-327
20. Buerk DG, Ances BM, Greenberg JH, et al: Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. Neuroimage 2003; 18:1-9
21. Iadecola C: Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5:347-360
22. Rosengarten B, Wolff S, Klatt S, et al: Effects of inducible nitric oxide synthase inhibition or norepinephrine on the neurovascular coupling in an endotoxic rat shock model. Crit Care 2009; 13:R139
23. Evora PR, Viaro F: The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target. Curr Drug Targets 2006; 7:1195-1204
24. Levin RL, Degrange MA, Bruno GF, et al: Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77:496-499
25. Mora-Ordóñez JM, Sánchez-Llorente F, Galeas-López JL, et al: Use of methylene blue in the treatment of vasoplegic syndrome of post-operative heart surgery. Med Intensiva 2006; 30:293-296
26. Donati A, Conti G, Loggi S, et al: Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 2002; 30:2271-2277
27. Maslow AD, Stearns G, Butala P, et al: The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006; 103:2-8
28. Sparicio D, Landoni G, Zangrillo A: Angiotensin-converting enzyme inhibitors predispose to hypotension refractory to norepinephrine but responsive to methylene blue. J Thorac Cardiovasc Surg 2004; 127:608
29. Martindale SJ, Stedeford JC: Neurological sequelae following methylene blue injection for parathyroidectomy. Anaesthesia 2003; 58: 1041-1042
30. Burrows GE: Methylene blue: Effects and disposition in sheep. J Vet Pharmacol Ther 1984; 7:225-231
31. Menardi AC, Capellini VK, Celotto AC, et al: Methylene blue administration in the compound 48/80-induced anaphylactic shock: Hemodynamic study in pigs. Acta Cir Bras 2011; 26:481-489
32. Osada S, Ichiki H, Oku H, et al: Participation of nitric oxide in mouse anaphylactic hypotension. Eur J Pharmacol 1994; 252:347-350
33. Mitsuhata H, Saitoh J, Hasome N, et al: Nitric oxide synthase inhibition is detrimental to cardiac function and promotes bronchospasm in anaphylaxis in rabbits. Shock 1995; 4:143-148
34. Mitsuhata H, Takeuchi H, Saitoh J, et al: An inhibitor of nitric oxide synthase, N omega-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock 1995; 3:447-453; discussion 454
35. Bellou A, Lambert H, Gillois P, et al: Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in Brown Norway rats anaphylactic shock. Shock 2003; 19:71-78
36. Zhang W, Shibamoto T, Cui S, et al: 7-nitroindazole, but not L-NAME or aminoguanidine, attenuates anaphylactic hypotension in conscious rats. Shock 2009; 31:201-206
37. Ndrepepa G, Schömig A, Kastrati A: Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: Looking for the reasons. JAMA 2007; 297:1711-1713
38. Wainwright M, Crossley KB: Methylene blue-A therapeutic dye for all seasons? J Chemother 2002; 14:431-443
39. Barnes RD, Ward LE, Frank KP, et al: Nitric oxide modulates evoked catecholamine release from canine adrenal medulla. Neuroscience 2001; 104:1165-1173
40. Kolo LL, Westfall TC, Macarthur H: Nitric oxide decreases the biological activity of norepinephrine resulting in altered vascular tone in the rat mesenteric arterial bed. Am J Physiol Heart Circ Physiol 2004; 286:H296-H303
41. Ward LE, Hunter LW, Grabau CE, et al: Nitric oxide reduces basal efflux of catecholamines from perfused dog adrenal glands. J Auton Nerv Syst 1996; 61:235-242
42. Peter C, Hongwan D, Küpfer A, et al: Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000; 56:247-250
43. Küpfer A, Aeschlimann C, Cerny T: Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996; 50:249-252
44. Naylor GJ, Martin B, Hopwood SE, et al: A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry 1986; 21:915-920
45. Miclescu A, Basu S, Wiklund L: Cardio-cerebral and metabolic effects of methylene blue in hypertonic sodium lactate during experimental cardiopulmonary resuscitation. Resuscitation 2007; 75:88-97
46. Wiklund L, Basu S, Miclescu A, et al: Neuro-and cardioprotective effects of blockade of nitric oxide action by administration of methylene blue. Ann N Y Acad Sci 2007; 1122:231-244
47. Martijn C, Wiklund L: Effect of methylene blue on the genomic response to reperfusion injury induced by cardiac arrest and cardiopulmonary resuscitation in porcine brain. BMC Med Genomics 2010; 3:27
48. Rolla G, Nebiolo F, Guida G, et al: Level of exhaled nitric oxide during human anaphylaxis. Ann Allergy Asthma Immunol 2006; 97:264-265
49. Gupta A, Lin RY, Pesola GR, et al: Nitric oxide levels in patients with acute allergic reactions. Internet J Asthma Allergy Immunol 2003; 3:1